A new peer-reviewed study1, conducted in collaboration with the Population Research Institute (PRI), shows that women who use Depo-Provera are significantly more likely to acquire HIV.
Due to funding from organizations like the Bill and Melinda Gates Foundation and agencies like the United Nations Population Fund (UNFPA), Depo-Provera is the most widely used form of birth control by women in Sub-Saharan Africa where HIV prevalence remains high.
The study found that Depo-Provera and other DMPA based injectable contraceptives increased women’s risk of acquiring HIV-1 by 49% compared to those not using hormonal contraception.
Depo-Provera, a pharmaceutical brand owned by Pfizer, Inc., is a long-term injectable contraceptive that prevents pregnancy for three months.
The active ingredient in Depo-Provera, and other injectable contraceptives like Depo Sub-Q Provera 104, is a progestin known as depot-medroxyprogesterone acetate (DMPA). DMPA based injectable contraceptives account for an estimated 70% of injectable contraceptives procured by non-governmental organizations (NGOs) and government agencies, like the UNFPA and the U.S. Agency for International Development (USAID).